NDA 203794 · Collegium Pharm INC
Nucynta
Tapentadol Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Oct 15, 2012
Approved uses
3
Original approval plus efficacy supplements
Registered trials
73
35 Phase 3, 1 recruiting
FAERS reports
28,531
26,313 serious, 19,844 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 14, 2024 Supplement 13 · Efficacy · priority review LetterLabelMedication Guide
- Jul 3, 2023 Supplement 10 · Efficacy · priority review LetterLabel
- Oct 15, 2012 Original approval · Type 3 - New Dosage Form ReviewREMSLabel
1 products under this application
- NUCYNTA · TAPENTADOL HYDROCHLORIDE EQ 20MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Tapentadol" as an intervention, any sponsor and status, largest first.
- An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00487435 · 1,166 participants · Start Jun 2007 · Primary completion Jun 2009
Drug: Tapentadol (CG5503) Extended Release (ER) · For: Pain; Osteoarthritis; Low Back Pain
Sites: Birmingham, Alabama; Hoover, Alabama; Mobile, Alabama · 148 sites in all
- A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00361504 · 1,123 participants · Start Nov 2006 · Primary completion Jul 2008
Drug: Oxycodone CR; Tapentadol (CG5503) ER · For: Osteoarthritis, Hip; Osteoarthritis, Knee; Lower Back Pain and 1 more
Sites: Mesa, Arizona; Tucson, Arizona; Anaheim, California · 52 sites in all
- Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.Pivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT01725087 · 1,089 participants · Start Nov 2012 · Primary completion Jul 2014
Drug: Matching Placebo; Low Dose GRT6005 and 3 more · For: Low Back Pain
Sites: Senftenberg, Austria; Vienna, Austria; Brussels, Belgium · 79 sites in all
- Tapentadol (CG5503)Pivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00421928 · 1,030 participants · Start Jan 2007 · Primary completion Jul 2008
Drug: oxycodone; placebo and 1 more · For: Osteoarthritis, Knee; Pain
- A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the KneePivotal-lookingCompleted
Grünenthal GmbHIndustry
NCT00486811 · 990 participants · Start Jun 2007 · Primary completion Jul 2008
Drug: Tapentadol ER (100 to 250 mg twice daily); Matching Placebo (twice daily) and 1 more · For: Pain; Knee Osteoarthritis
Sites: Innsbruck, Austria; Mitterdorf, Austria; Salzburg, Austria · 100 sites in all
- A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00449176 · 981 participants · Start Feb 2007 · Primary completion May 2008
Drug: tapentadol (CG5503) ER; oxycodone CR and 1 more · For: Low Back Pain
- A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.Pivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00613938 · 901 participants · Start Feb 2008 · Primary completion Oct 2008
Drug: Tapentadol (CG5503); Tapentadol (CG5503) and 2 more · For: Arthralgia; Bunion; Hallux Valgus and 1 more
Sites: Glendale, California; Pasadena, Maryland; Austin, Texas · 7 sites in all
- A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00364546 · 877 participants · Start Jul 2006 · Primary completion Jun 2007
Drug: CG 5503;tapentadol · For: Osteoarthritis; Pain Intensity Assessment; Arthralgia and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death11,509
- toxicity to various agents9,269
- overdose5,778
- drug abuse1,400
- drug dependence962
- drug withdrawal syndrome neonatal916
- accidental overdose656
- drug ineffective583
- pain485
- nausea443
- intentional product misuse350
- fatigue281
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 95 |
| 2010 | 142 |
| 2011 | 287 |
| 2012 | 283 |
| 2013 | 213 |
| 2014 | 233 |
| 2015 | 709 |
| 2016 | 819 |
| 2017 | 2,271 |
| 2018 | 21,364 |
| 2019 | 458 |
| 2020 | 386 |
| 2021 | 239 |
| 2022 | 245 |
| 2023 | 245 |
| 2024 | 281 |
| 2025 | 215 |
| 2026 | 44 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nucynta (Tapentadol HCl)
2024 spending
$56.1M
Beneficiaries
9,123
53,809 claims
Per beneficiary
$6,150
$12.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $50,695,015 |
| 2021 | $53,796,706 |
| 2022 | $57,046,571 |
| 2023 | $58,810,957 |
| 2024 | $56,108,628 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review.
D'Souza RS, Barman R, Joseph A, et al. · Curr Pain Headache Rep 2022 · Systematic Review
- Opioids for cancer pain - an overview of Cochrane reviews.
Wiffen PJ, Wee B, Derry S, et al. · Cochrane Database Syst Rev 2017 · Research Support, Non-U.S. Gov't, Systematic Review
- Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients.
Roulet L, Rollason V, Desmeules J, et al. · Drugs 2021 · Systematic Review
- Reducing Opioid Use for Chronic Pain With a Group-Based Intervention: A Randomized Clinical Trial.
Sandhu HK, Booth K, Furlan AD, et al. · JAMA 2023 · Multicenter Study, Randomized Controlled Trial
- Oral tapentadol for cancer pain.
Wiffen PJ, Derry S, Naessens K, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Opioid Rotation in Cancer Pain Treatment.
Schuster M, Bayer O, Heid F, et al. · Dtsch Arztebl Int 2018 · Systematic Review
Sponsor: Collegium Pharm INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.